Mallinckrodt Sues Rival Over Patent Infringement on Injectable Acetaminophen

Mallinckrodt Pharmaceuticals has initiated legal action against a competing drug manufacturer in Delaware federal court. The company alleges that the rival has unlawfully replicated its injectable version of acetaminophen, violating four of Mallinckrodt’s patents in the process. The case underscores ongoing tensions in the pharmaceutical industry over intellectual property rights, particularly surrounding high-demand medications. Further details are available in the full article on Law360.